Chloroquine
Aminoquinolines
- Drug class
- Aminoquinolines
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 6
Overview
Chloroquine is an active pharmaceutical ingredient in the Aminoquinolines group (P01BA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 4 | April 24, 2026 |
| US United States | FDA | 2 | January 13, 2026 |
GBUnited Kingdom· MHRA
4 products
Uses
a) Treatment of malaria. b) Prophylaxis and suppression of malaria. c) Treatment of amoebic hepatitis and abscess. d) Treatment of discoid and systemic lupus erythematosus. e) Treatment of rheumatoid arthritis.
How to take
USUnited States· FDA
2 products
Uses
INDICATIONS AND USAGE
Chloroquine phosphate tablets are indicated for the:
Treatment of uncomplicated malaria due to susceptible strains of P. malariae, P. vivax . Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites.
, cerebral malaria or acute renal failure). Do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to chloroquine phosphate tablets is widespread in P. vivax (see WARNINGS ).
ovale (see DOSAGE AND ADMINISTRATION ).
Drug interactions
Known interactions involving Chloroquine. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 426. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL168530143 · revised October 31, 2025
- [2]FDA DailyMed · 06c69e2b-211b-47… · revised October 1, 2024 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.